Aristea Translational Medicine Corp
Aims are commercialization of a patent pending drug for Concussion and prevention of secondary Chronic Traumatic Encephalopathy and Alzheimer's disease .
Aristea has developed a drug with demonstrated effectiveness against Concussion (mild Traumatic Brain Injury) in a mouse model. No drug treatment can currently reduce the pathology following Concussion or the increased risks of later onset Chronic Traumatic Encephalopathy or Alzheimer's disease. With extensive human safety already demonstrated our drug is ready to enter clinical trials. A patent is pending.